Covid-19 manufacturing roundup: Catalent gets the FDA's go-ahead on J&J shot; AstraZeneca taps a new contractor
The FDA has authorized an Indiana CDMO to produce and ship millions of doses of J&J’s Covid-19 vaccine.
Catalent Pharma tweeted the news and an accompanying video from its Bloomington facility last week. The manufacturer received a EUA, which puts J&J a step closer toward meeting its goal of providing the US with 100 million doses by the end of June.
Today, Catalent is proud to share that our Bloomington, Indiana site’s recently completed expansion received Emergency Use Authorization from the FDA to produce and ship millions of doses of Johnson & Johnson’s COVID-19 vaccine. Learn more: https://t.co/jFg5OoWkyO @JNJNews pic.twitter.com/rDhSl8Uois
— Catalent Pharma (@CatalentPharma) March 23, 2021
That approval comes as Maryland’s Emergent BioSolutions, another contractor on the J&J shot, awaits a EUA. Emergent made headlines Wednesday when The New York Times reported that a mix-up between the vectors used in J&J and AstraZeneca’s vaccines put a batch of the vaccine — which the Times said translated to 15 million doses — at risk.
AstraZeneca gains Covid-19 vaccine manufacturing partner
Despite a tumultuous week for AstraZeneca fueled by restrictions placed on the use of its vaccine in Germany and France after a report the shot could lead to blood clots in young women, the company announced it will enter a manufacturing agreement with Japan’s Ajinomoto Bio-Pharma on Tuesday.
The agreement expands the scope of services to include fill-finish services at a San Diego facility as well as small molecule manufacturing in Belgium, according to a news release.
“Our San Diego team is proud to join our Belgium colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients,” said Ajinomoto Global Account Manager Magnus Busch in a statement.
Kicking off a busy seven-day stretch, AstraZeneca denied claims earlier this week that it is stockpiling doses of its Covid-19 vaccine at its Anagni plant in Italy after Italian police raided a storage facility and found 29 million doses last week.
“It is incorrect to describe this as a stockpile,” a statement said. “The process of manufacturing vaccines is very complex and time consuming.”
To meet Covid-19 demands, Pall to open plant in SC
In an effort to increase capacity to meet the demand for vaccine production, Pall Corporation has acquired a new manufacturing plant in Spartanburg County, SC.
The facility will focus on single-use technology, such as the Allegro system, which is designed for use across a range of activities such as sterile filtration, virus filtration, virus inactivation and pH adjustment, among others.
The company also announced the acquisition of China-based Pall-Austar Lifesciences Limited, as a part of a $114 million deal that increases production at seven of its facilities. Those facilities are Medemblik, Netherlands; Hoegaarden, Belgium; Bad Kreuznach, Germany; Ilfracombe and Newquay, UK; Fajardo, Puerto Rico and Pensacola, FL.
The expansion is expected to add 1,100 jobs during 2021, a release said.